Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Natural History of the Progression of Stargardt Disease: Retrospective and Prospective Studies

Study:

The Natural History of the Progression of Atrophy Secondary to Stargardt Disease: A Retrospective Longitudinal Observational Study, and The Natural History of the Progression of Atrophy Secondary to Stargardt Disease: A Prospective Longitudinal Observational Study

Rationale:

n/a

Purpose:

Stargardt disease is currently an incurable and untreatable macular dystrophy that causes severe visual loss in children and young adults, thereby causing enormous morbidity with economic, psychological, emotional, and social implications. There are no FDA approved therapeutic treatments for this disease. Therefore, the objective of this study is to collect natural history data from a large population of children and adults in order to evaluate possible efficacy measures for planned clinical trials. Participants will be recruited from each Investigator`s own patient population as the study requires the availability of both multiyear retrospective data, as well as ongoing prospectively collected data.

Study Status: Recruiting

Recruiting:
Meghan Marino, MS marinom2@ccf.org

Condition Intervention Phase
Stargardt Disease n/a N/A

Verified by Foundation Fighting Blindness Clinical Research Institute November, 2013

Sponsored by: Foundation Fighting Blindness Clinical Research Institute
Information provided by: Foundation Fighting Blindness Clinical Research Institute
ClinicalTrials.gov identifier: NCT01977846

Study Type: Interventional

Study Design: Observational Model: Case-Only

Cole Eye Institute, Cleveland Clinic
Cleveland, Ohio 44195
United States

Hendrik Scholl, MD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site